Efficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study
IntroductionPatients with extensive-stage small cell lung cancer (ES-SCLC) have a poor Q6 prognosis and there is no standard protocol for maintenance treatment. Anlotinib as a third-line or beyond therapy for ES-SCLC was proved to be effective.MethodsWe retrospectively screened of patients with ES-S...
Saved in:
Main Authors: | Jin Xiong, Lei Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1462581/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01) -
Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report
by: Ranran Li, et al.
Published: (2025-02-01) -
Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
by: Jiaxuan Liu, et al.
Published: (2025-01-01) -
Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks
by: Elena Díaz-Santiago, et al.
Published: (2025-01-01) -
First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Rong Long, et al.
Published: (2024-12-01)